All News

BMS, which has a rapidly developing and successful immunooncology pipeline, has entered into a collaboration with CytomX to develop their Probody Therapeutics antibody platform. The Probody technology improves efficacy and safety as the antibodies are activated only in the disease microenvironment and not in normal tissue.

Recent controversy over the cost of Sovaldi (Gilead Sciences)-a $1000-per-dose treatment for hepatitis C-has sparked a debate as to whether there should be federal caps on the costs of certain prescription drugs.

1.5 Credits - CME/CPE | Expires 05/15/2015

The CMS has unveiled two initiatives that could significantly affect pay and operations for Medicaid managed-care plans and healthcare providers serving millions of low-income and disabled Americans.

One of the biggest beneficiaries of the health law's expansion of coverage to more than 13 million people this year has been the nation's safety-net hospitals, which treat a disproportionate share of poor and uninsured people and therefore face billions of dollars in unpaid bills.

New York's safety net providers have a new impetus and incentive to collaborate on redesigning how they serve Medicaid patients - if they can make all the moving pieces work.

Advocates for a single-payer Medicare for all health system are fanning out across Capitol Hill this week, lobbying members of Congress.

An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer. In just a few years' time, Ipilumumab could be approved as a treatment for the world's third-most common type of cancer.

A new chemotherapy drug (alisertib or MLN8237) being investigated for its potency against two types of cancer was found by scientists to be effective in about one-third of the 58 patients who participated in a phase I study.

Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer Approval Reinforces Amgen Commitment to Personalized Medicine.

Chronically ill patients, who are more likely to require necessary care, should pay less for health insurance, Aaron E. Carroll, a professor of pediatrics at Indiana University School of Medicine, argued in an op-ed for the New York Times.

A new report highlights the ways hospitals can identify and address sources of "avoidable suffering" and ultimately improve the patient experience.

Federally qualified health centers (FQHCs) have increased their EHR adoption by 133% over the past four years, says a report from The Commonwealth Fund, with 93% of FQHCs in possession of an EHR and 85% of these community provider organizations reporting advanced HIT capabilities.

The patient-centered medical home model in Arkansas, which has more than 600 participating providers, helps the state's Medicaid program incentivize quality care instead of paying for volume of services.

A change to provisions in the Affordable Care Act (ACA) would allow insurers to receive federal funding for any financial losses they endured due to the health law.

1.0 Credit - CME/CPE | Expires 4/18/2015

Trials conducted at the Abramson Cancer Center among others have identified the potential of an antimalarial agent, hydroxychloroquine, in stabilizing aggressive cancers.

EU's Committee for Medicinal Products for Human Use (CHMP)supported the use of Gazyvaro based on the phase III CLL11 study, wherein treatment with Gazyvaro (obinutuzumab) plus chlorambucil significantly reduced the risk of disease worsening or death by 86% and increased survival time for previously untreated CLL patients compared to those who received treatment with chlorambucil alone.

Scientists at Cold Spring Harbor Laboratory (CSHL) today report a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer.

A CMS proposal could extend the deadline for providers to transition to Stage 2 meaningful use of electronic health records (EHRs). Agency officials said they have received extensive feedback from health providers who felt they did not have enough time to efficiently transition their EHR systems.

A research article published in Nature Communications identifies a new mechanism of breast cancer metastasis.

'Encouraging' Period of Stable Disease Suggested in Direct Injection Vaccine Treatment of Pancreatic Cancer. Research from Rutgers Cancer Institute of New Jersey to be presented at the Pancreatic Cancer-focused meeting held by AACR in New Orleans.

Amid strong lobbying by business groups, support is growing to end the Affordable Care Act's employer mandate, a change that would see millions more Americans buying their health insurance through exchanges.

A new study estimates that it would cost Medicare about $2 billion a year to screen certain current and former heavy smokers for lung cancer.

As part of a contract extension with Tenet Healthcare, Cigna has established a first of its kind quality-based reimbursement agreement.

A CMS ruling would force healthcare providers to enroll in Medicare by June 1, 2015, if they plan to prescribe medications that are paid for by the program. The agency said in a report that changes to Medicare Part D were necessary in order to cut down on inappropriate prescription practices and to improve patient safety.

NICE rejected Celgene's Revlimid again for treating patients with myelodysplastic syndrome, quoting concerns with cost-effectiveness of the drug.

CO-1686 was assigned breakthrough designation by the FDA as monotherapy for the treatment of EGFR-mutant NSCLC patients.

Results presented at the 2014 American Urological Association (AUA) meeting in Florida revealed that Myriad's prostate cancer diagnostic test could predict mortality risk in prostate cancer.